Skip to main content

Advertisement

SpringerLink
Log in

Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective

  • Invited Review Article
  • Published:
Cardiovascular Intervention and Therapeutics Aims and scope Submit manuscript

Abstract

Antiplatelet therapy, the cornerstone of post coronary stenting antithrombotic therapy, reduces the rate of hard clinical endpoints in patients treated both conservatively and invasively following an acute coronary syndrome, as well as in those patients with chronic stable coronary disease who receive a coronary stent. The development of newer antiplatelet and direct anticoagulant agents provides new options in the antithrombotic management of patients with coronary artery disease, enabling different therapeutic combinations to be tailored to an individual patient’s bleeding and ischemic risk profile. In this review, we will summarize the history of dual antiplatelet therapy, discuss the latest evidence and future perspectives in treating patients with coronary artery disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

ACS:

Acute coronary syndrome

MI:

Myocardial infarction

DES:

Drug eluting stent

RCT:

Randomized controlled trial

DOAC:

Direct oral anticoagulant

IVUS:

Intravascular ultrasound

SIHD:

Stable ischemic heart disease

PCI:

Percutaneous coronary intervention

References

  1. Capodanno D, Ingala S, Calderone D, Angiolillo DJ. Aspirin for the primary prevention of cardiovascular disease: latest evidence. Expert Rev Cardiovasc Ther. 2019;17:1–11.

    CAS  Google Scholar 

  2. Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events—A meta-analysis. Int J Cardiol. 2008;128:166–71.

    PubMed  Google Scholar 

  3. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell’Angina Instabile Group. Circulation. 1990;82:17–26.

    CAS  PubMed  Google Scholar 

  4. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676–88.

    CAS  PubMed  Google Scholar 

  5. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665–71.

    CAS  PubMed  Google Scholar 

  6. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. Circulation. 1998;98:1597–603.

    CAS  PubMed  Google Scholar 

  7. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084–9.

    PubMed  Google Scholar 

  8. Féliste R, Delebassée D, Simon MF, Chap H, Defreyn G, Vallée E, et al. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb Res. 1987;48:403–15.

    PubMed  Google Scholar 

  9. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409:202–7.

    CAS  PubMed  Google Scholar 

  10. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000;102:624–9.

    CAS  PubMed  Google Scholar 

  11. O’Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies. Circulation. 2006;114:e600–6.

    PubMed  Google Scholar 

  12. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54:2430–5.

    CAS  PubMed  Google Scholar 

  13. Muller C, Caillard S, Jesel L, El Ghannudi S, Ohlmann P, Sauleau E, et al. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis. 2012;59:777–85.

    CAS  PubMed  Google Scholar 

  14. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Plavix reduction of new thrombus occurrence (PRONTO) trial. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the plavix reduction of new thrombus occurrence (PRONTO) trial. Am Heart J. 2003;145:239–47.

    CAS  PubMed  Google Scholar 

  15. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Circulation. 2005;111:2099–106.

    CAS  PubMed  Google Scholar 

  16. Weber AA, Braun M, Hohlfeld T, Schwippert B, Tschöpe D, Schrör K. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol. 2001;52:333–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49:2312–7.

    CAS  PubMed  Google Scholar 

  18. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation. 1999;99:2364–6.

    CAS  PubMed  Google Scholar 

  19. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. J Am Coll Cardiol. 2005;46:1827–32.

    CAS  PubMed  Google Scholar 

  20. Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J. 2008;156:10S–5S.

    CAS  Google Scholar 

  21. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.

    CAS  PubMed  Google Scholar 

  22. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J. 2008;29:2473–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118:1626–36.

    CAS  PubMed  Google Scholar 

  24. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardio-thoracic Surg. 2018;53:34–78.

    Google Scholar 

  25. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA Guideline for the management of st-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-Elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134:123–55.

    Google Scholar 

  26. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–35.

    CAS  PubMed  Google Scholar 

  27. Xie Y, Mintz GS, Yang J, Doi H, Iñiguez A, Dangas GD, et al. Clinical outcome of nonculprit plaque ruptures in patients with acute coronary syndrome in the PROSPECT study. JACC Cardiovasc Imaging. 2014;7:397–405.

    PubMed  Google Scholar 

  28. Costa F, Valgimigli M. The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short. Cardiovasc Diagn Ther. 2018;8:630–46.

    PubMed  PubMed Central  Google Scholar 

  29. Kwok CS, Rao SV, Myint PK, Keavney B, Nolan J, Ludman PF, et al. Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis. Open Heart. 2014;1:e000021.

    PubMed  PubMed Central  Google Scholar 

  30. Amin AP, Wang TY, McCoy L, Bach RG, Effron MB, Peterson ED, Cohen DJ. Impact of bleeding on quality of life in patients on DAPT: insights from TRANSLATE-ACS. J Am Coll Cardiol. 2016;67:59–65.

    PubMed  Google Scholar 

  31. Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv. 2009;2:222–9.

    PubMed  Google Scholar 

  32. Valle JA, Shetterly S, Maddox TM, Ho PM, Bradley SM, Sandhu A, et al. Postdischarge bleeding after percutaneous coronary intervention and subsequent mortality and myocardial infarction: insights from the HMO research network-stent registry. Circ Cardiovasc Interv. 2016;9:e003519.

    PubMed  Google Scholar 

  33. Dangas GD, Claessen BE, Mehran R, Brener S, Brodie BR, Dudek D, et al. Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol. 2012;59:1752–9.

    PubMed  Google Scholar 

  34. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–505.

    PubMed  Google Scholar 

  35. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, et al. Development and validation of a prediction rule for benefit and harm of Dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735–49.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Beatty AL, Ku IA, Bibbins-Domingo K, Christenson RH, DeFilippi CR, Ganz P, et al. Traditional risk factors versus biomarkers for prediction of secondary events in patients with stable coronary heart disease: from the Heart and Soul Study. J Am Heart Assoc. 2015;4:e001646.

    PubMed  PubMed Central  Google Scholar 

  37. Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2015;37:390–9.

    PubMed  Google Scholar 

  38. Palmerini T, Bruno AG, Gilard M, Morice MC, Valgimigli M, Montalescot G, Collet JP, et al. Risk-benefit profile of longer-than-1-year dual-antiplatelet therapy duration after drug-eluting stent implantation in relation to clinical presentation. Circ Cardiovasc Interv. 2019;12:e007541.

    CAS  PubMed  Google Scholar 

  39. Costa F, Vranckx P, Leonardi S, Moscarella E, Ando G, Calabro P, et al. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY Prolonging Dual-Antiplatelet Treatment After. Eur Heart J. 2015;36:1242–51.

    PubMed  Google Scholar 

  40. Ueda P, Jernberg T, James S, Alfredsson J, Erlinge D, Omerovic E, et al. External validation of the DAPT score in a nationwide population. J Am Coll Cardiol. 2018;71:A2111.

    Google Scholar 

  41. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.

    CAS  PubMed  Google Scholar 

  42. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381:1309–20.

    PubMed  Google Scholar 

  43. Palmerini T, Barozzi C, Tomasi L, Riva DD, Marengo M, Cicoria G, et al. In vitro thrombogenicity of drug-eluting and bare metal stents. Thromb Res. 2020;185:43–8.

    CAS  PubMed  Google Scholar 

  44. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321:2414–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Iqbal MB, Nadra IJ, Ding L, Fung A, Aymong E, Chan AW, et al. Long-term outcomes following drug-eluting stents versus bare metal stents for primary percutaneous coronary intervention: a real-world analysis of 11,181 patients from the british columbia cardiac registry. Catheter Cardiovasc Interv. 2016;88:24–35.

    PubMed  Google Scholar 

  46. Philip F, Stewart S, Southard JA. Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: network meta-analysis of randomized primary percutaneous coronary intervention trials. Catheter Cardiovasc Interv. 2016;88:38–48.

    PubMed  Google Scholar 

  47. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373:2038–47.

    CAS  PubMed  Google Scholar 

  48. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.

    CAS  PubMed  Google Scholar 

  49. Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999;33:634–9.

    CAS  PubMed  Google Scholar 

  50. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet. 2001;358:527–33.

    CAS  PubMed  Google Scholar 

  51. Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381:1524–34.

    PubMed  Google Scholar 

  52. Evidence Review Committee Members, Bittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;2016(68):1116–39.

    Google Scholar 

  53. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39:213–54.

    PubMed  Google Scholar 

  54. Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65:805–15.

    CAS  PubMed  Google Scholar 

  55. Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrié D, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2018;391:41–50.

    CAS  PubMed  Google Scholar 

  56. Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrié D, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025–34.

    Google Scholar 

  57. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of xience/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125:505–13.

    CAS  PubMed  Google Scholar 

  58. Schulz-Schüpke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, et al. ISAR-SAFE: A randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015;36:1252–63.

    PubMed  Google Scholar 

  59. De Luca G, Damen SA, Camaro C, Benit E, Verdoia M, Rasoul S, et al. Final results of the Randomised Evaluation of short-term DUal antiplatelet therapy in patients with acute Coronary syndromE treated with a new generation stent (REDUCE) trial. EuroIntervention. 2019;15:e990–8.

    PubMed  Google Scholar 

  60. Collet JP, Silvain J, Barthélémy O, Rangé G, Cayla G, Van Belle E, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-interruption): a randomised trial. Lancet. 2014;384:1577–85.

    CAS  PubMed  Google Scholar 

  61. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-Term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–800.

    PubMed  Google Scholar 

  62. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919–33.

    CAS  PubMed  Google Scholar 

  63. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390:1747–57.

    CAS  PubMed  Google Scholar 

  64. Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38:3070–8.

    CAS  PubMed  Google Scholar 

  65. Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, et al. Bedside Monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367:2100–9.

    CAS  PubMed  Google Scholar 

  66. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433–41.

    CAS  PubMed  Google Scholar 

  67. Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: jACC state-of-the-art review. J Am Coll Cardiol. 2019;74:83–99.

    PubMed  Google Scholar 

  68. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective-2018 update. Circulation. 2018;138:527–36.

    CAS  PubMed  Google Scholar 

  69. Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019;83:1085–196.

    CAS  PubMed  Google Scholar 

  70. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107–15.

    CAS  PubMed  Google Scholar 

  71. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423–34.

    CAS  PubMed  Google Scholar 

  72. Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019;40:1553–62.

    PubMed  PubMed Central  Google Scholar 

  73. Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS Trial. Circulation. 2019. https://doi.org/10.1161/CIRCULATIONAHA.119.044584.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394:1335–43.

    CAS  PubMed  Google Scholar 

  75. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, Valgimigli M. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomiz. Eur Heart J. 2019;40:3757–67.

    PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. GVM Care and Research, Maria Cecilia Hospital, Cotignola, Ravenna, Italy

    Antonio Mangieri, Francesco Gallo, Alessandro Sticchi, Arif A. Khokhar, Alessandra Laricchia, Francesco Giannini & Antonio Colombo

Authors
  1. Antonio Mangieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Gallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Sticchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arif A. Khokhar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alessandra Laricchia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francesco Giannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antonio Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Mangieri.

Ethics declarations

Conflict of interest

Antonio Mangieri received an institutional grant (unrestricted grant) from Boston scientific; he received a research fee from Innovative Cardiac Solution. Francesco Giannini serves as proctor for Neovasc. Other authors have no conflict of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mangieri, A., Gallo, F., Sticchi, A. et al. Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective. Cardiovasc Interv and Ther 35, 117–129 (2020). https://doi.org/10.1007/s12928-020-00642-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12928-020-00642-w

Keywords

Search

Navigation